Media coverage about Abbott Laboratories (NYSE:ABT) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abbott Laboratories earned a news impact score of 0.12 on Accern’s scale. Accern also gave news headlines about the healthcare product maker an impact score of 44.4740207645421 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Abbott Laboratories (ABT) Holdings Cut by Tufton Capital Management (americanbankingnews.com)
- Abbott Laboratories (ABT) Shares Sold by Highland Capital Management LLC (americanbankingnews.com)
- Abbott Laboratories (ABT) Shares Sold by Pillar Pacific Capital Management LLC (americanbankingnews.com)
- Abbott Laboratories (ABT) Position Trimmed by Moloney Securities Asset Management LLC (americanbankingnews.com)
- FTB Advisors Inc. Has $1.37 Million Position in Abbott Laboratories (ABT) (americanbankingnews.com)
Abbott Laboratories (ABT) traded up $0.72 during trading hours on Friday, reaching $59.71. The company had a trading volume of 5,118,397 shares, compared to its average volume of 7,770,000. The stock has a market capitalization of $103,930.00, a price-to-earnings ratio of 57.41, a PEG ratio of 1.79 and a beta of 1.55. Abbott Laboratories has a 52-week low of $42.31 and a 52-week high of $64.60. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.26 and a current ratio of 2.26.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be issued a $0.28 dividend. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $1.12 dividend on an annualized basis and a yield of 1.88%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 107.69%.
ABT has been the subject of several recent analyst reports. Zacks Investment Research cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Royal Bank of Canada reissued a “buy” rating and set a $65.00 target price on shares of Abbott Laboratories in a research note on Tuesday, January 9th. Evercore ISI began coverage on Abbott Laboratories in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $64.00 target price for the company. ValuEngine upgraded Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, November 22nd. Finally, BTIG Research lowered Abbott Laboratories from a “buy” rating to a “neutral” rating in a research report on Monday, January 22nd. They noted that the move was a valuation call. Eight investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $65.47.
In related news, insider Stephen R. Fussell sold 56,401 shares of Abbott Laboratories stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $59.61, for a total value of $3,362,063.61. Following the completion of the transaction, the insider now directly owns 184,884 shares in the company, valued at $11,020,935.24. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Stephen R. Fussell sold 13,313 shares of Abbott Laboratories stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $62.84, for a total value of $836,588.92. Following the completion of the transaction, the executive vice president now owns 152,343 shares of the company’s stock, valued at $9,573,234.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 405,137 shares of company stock valued at $22,686,356. 0.76% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3222014/abbott-laboratories-abt-receives-media-impact-score-of-0-12.html.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.